S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
NASDAQ:VSTM

Verastem - VSTM Stock Forecast, Price & News

$1.27
+0.06 (+4.96%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.22
$1.27
50-Day Range
$1.04
$1.43
52-Week Range
$1.00
$3.58
Volume
4.82 million shs
Average Volume
937,420 shs
Market Capitalization
$238.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.33

Verastem MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
319.9% Upside
$5.33 Price Target
Short Interest
Healthy
2.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.33mentions of Verastem in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$14,779 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.42) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

410th out of 1,135 stocks

Pharmaceutical Preparations Industry

206th out of 557 stocks

VSTM stock logo

About Verastem (NASDAQ:VSTM) Stock

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Verastem from a "sell" rating to a "hold" rating in a report on Friday, May 20th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $5.33.

Verastem Trading Up 5.0 %

Shares of VSTM opened at $1.27 on Friday. Verastem has a 12 month low of $1.00 and a 12 month high of $3.58. The stock's 50-day moving average is $1.17 and its two-hundred day moving average is $1.29. The company has a debt-to-equity ratio of 0.46, a current ratio of 4.87 and a quick ratio of 6.72. The stock has a market cap of $238.52 million, a PE ratio of -2.95 and a beta of 0.78.

Verastem (NASDAQ:VSTM - Get Rating) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). Verastem had a negative return on equity of 100.92% and a negative net margin of 2,007.44%. Equities analysts forecast that Verastem will post -0.42 earnings per share for the current fiscal year.

Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

VSTM Stock News Headlines

Verastem: Q2 Earnings Snapshot
Is Verastem (NASDAQ:VSTM) Using Too Much Debt?
See More Headlines
Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

VSTM Company Calendar

Last Earnings
8/08/2022
Today
8/14/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VSTM
CUSIP
92337C10
Fax
N/A
Employees
48
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.33
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+319.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-71,200,000.00
Net Margins
-2,007.44%
Pretax Margin
-2,487.46%

Debt

Sales & Book Value

Annual Sales
$2.05 million
Book Value
$0.29 per share

Miscellaneous

Free Float
182,362,000
Market Cap
$238.52 million
Optionable
Optionable
Beta
0.78

Key Executives

  • Mr. Brian M. Stuglik BPHARM (Age 63)
    R.Ph., RPh, CEO & Director
    Comp: $1.04M
  • Mr. Daniel W. Paterson (Age 61)
    COO & Pres
    Comp: $710.39k
  • Mr. Robert E. Gagnon (Age 48)
    Chief Bus. & Financial Officer
    Comp: $609.39k
  • Mr. Richard H. Aldrich M.B.A. (Age 68)
    Mba, Founder and Consultant
  • Dr. Robert A. Weinberg Ph.D.
    Co-Founder & Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta Ph.D.
    Co-Founder
  • Dr. Michelle Dipp M.D. (Age 46)
    Ph.D., Co-Founder
  • Dr. Jonathan Pachter Ph.D. (Age 64)
    Chief Scientific Officer
  • Ms. Erin S. Cox
    Sr. Director of Investor Relations & Corp. Communications
  • Mr. Sean C. Flynn (Age 48)
    VP, Gen. Counsel & Sec.













VSTM Stock - Frequently Asked Questions

Should I buy or sell Verastem stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VSTM shares.
View VSTM analyst ratings
or view top-rated stocks.

What is Verastem's stock price forecast for 2022?

4 brokers have issued 12-month target prices for Verastem's stock. Their VSTM share price forecasts range from $5.00 to $6.00. On average, they expect the company's share price to reach $5.33 in the next year. This suggests a possible upside of 319.9% from the stock's current price.
View analysts price targets for VSTM
or view top-rated stocks among Wall Street analysts.

How have VSTM shares performed in 2022?

Verastem's stock was trading at $2.05 at the start of the year. Since then, VSTM shares have decreased by 38.0% and is now trading at $1.27.
View the best growth stocks for 2022 here
.

When is Verastem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our VSTM earnings forecast
.

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) announced its earnings results on Monday, August, 8th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.01. Verastem had a negative net margin of 2,007.44% and a negative trailing twelve-month return on equity of 100.92%.

What is Robert Forrester's approval rating as Verastem's CEO?

11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

Who are Verastem's major shareholders?

Verastem's stock is owned by a number of retail and institutional investors. Top institutional investors include Eagle Asset Management Inc. (2.99%), Artisan Partners Limited Partnership (1.03%), ClariVest Asset Management LLC (0.47%), Renaissance Technologies LLC (0.18%), Northern Trust Corp (0.16%) and Russell Investments Group Ltd. (0.15%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Ra Capital Management, LP, Robert E Gagnon and Timothy J Barberich.
View institutional ownership trends
.

How do I buy shares of Verastem?

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $1.27.

How much money does Verastem make?

Verastem (NASDAQ:VSTM) has a market capitalization of $238.52 million and generates $2.05 million in revenue each year. The biopharmaceutical company earns $-71,200,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The official website for the company is www.verastem.com. The biopharmaceutical company can be reached via phone at (781) 292-4200 or via email at bsullivan@verastem.com.

This page (NASDAQ:VSTM) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.